

| SEARCHED | | | |
|----------|-------|-----------|-------|
| Class | Sub. | Date | Exmr. |
| 424 | 131.1 | 14 Apr 99 | 9B |
| 530 | 387.2 | | |
| 435 | 327 | | |
| | 91.1 | | |
| 536 | 23.53 | | |
| | 23.4 | | |
| 536 | 23.5 | 2/21/02 | SR |
| 530 | 388.1 | 3/12/02 | SR |
| | 387.2 | | |
| | 388.8 | | |
| | 387.3 | | |
| 435 | 320.1 | | |
| | 325 | | |
| | 70.1 | | |
| 536 | 24.3 | | |
| 424 | 131.1 | | |
| | 135.1 | | |
| | 138.1 | | |
| | 185.1 | | |
| Update 2 | | 1/5/03 | SR |

| INTERFERENCE SEARCHED | | | |
|-----------------------|------|------|-------|
| Class | Sub. | Date | Exmr. |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | |
|-----|--------------|----------|
| 33. | Weller | 9-26-02 |
| 34. | Asso. PA | 9-26-02 |
| 35. | F. Mail by 2 | 2-11-03 |
| 36. | Edgerton (3) | 8-11-03 |
| 37. | PCE | 8-11-03 |
| 38. | Unst G | 8-11-03 |
| 39. | 16 2 | 12/17/03 |
| 40. | | |
| 41. | | |
| 42. | | |
| 43. | | |
| 44. | | |
| 45. | | |

| SEARCH NOTES | | |
|---|-----------|-------|
| | Date | Exmr. |
| discussed 112 issues w/ examiner, then look + handle m88 | 5/5/99 | 9B |
| Searched Seq IDs 1-4 in protein + dna database + CDR regions of Seq IDs 1-4 | 20 Apr 99 | 9B |
| Searched inventors + keywords at ADS, STN, Dials | 14 Apr 99 | 9B |
| 08/766350 | 3/12/02 | SR |
| SEQUENCE SEARCH N-MER: SERED NOS. 1+3 all commercial na databases | 2/21/02 | SR |
| 60/035345 | 3/12/02 | SR |
| WEST -11010 -Chatterjee, M. | 3/12/02 | SR |
| BIO SCIENCE (STN) -see search notes attached | 3/12/02 | SR |
| 60/031,306 -see note attached | 3/15/02 | SR |
| Conferred with Anthony Caputo | 3/13/02 | SR |
| SEQUENCE SEARCH SEQ ID NOS. 1-4 | 3/19/02 | SR |
| Update 2 | 1/5/03 | SR |

SEARCH NOTES CON'T

updated 11/25/03 SR

SEQ SEARCH 8/31/03 SR
 SEQ ID NOS. 1, 2,
 3, & 4
 - commercial &
 interference databases

10/367506 11/25/03 SR

Conferred w/ Brian
 Stanton re. utility and
 scope of enablement -
 advised to drop utility
 and maintain scope
 of enablement req.

Conferred w/ Larry
 Helms re. scope of
 enablement - advised to
 drop enablement req unless
 claims are limited to scFv
 antibodies without a
 linker

Conferred w/ Larry
 Helms re. utility of
 claimed "immunogenic
 compositions" comprising
 a polynucleotide - advised
 to rephrase claims under 101 as
 lacking utility